Loading…
Loading…
DBV Technologies (NASDAQ: DBVT - Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ: ARWR - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations. Risk and Volatility DBV Technologies has a beta
DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) shares reached a new 52-week low during mid-day trading on Wednesday. The stock traded as low as $8.90 and last traded at $9.03, with a volume of 344,103 shares traded. The stock had previously closed at $9.55. Analyst Ratings Changes A number of equities research analysts have
Shares of DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) hit a new 52-week low on Thursday. The company traded as low as $9.64 and last traded at $9.77, with a volume of 535276 shares changing hands. The stock had previously closed at $9.98. Analysts Set New Price Targets A number of brokerages have issued
DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) shares gapped down prior to trading on Thursday. The stock had previously closed at $11.76, but opened at $11.30. DBV Technologies shares last traded at $11.32, with a volume of 90,769 shares traded. Analyst Upgrades and Downgrades Several research firms recently commented on DBVT. Cantor Fitzgerald restated
Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Ap p lication to U.S. FDA for the VIASKIN ® Peanut Patch in Children Aged 4-7 Years The BLA is supported by the results from the successful Phase 3 VITESSE trial – the largest immunotherapy clinical trial to date for this population. DBV has requested Priority Review of the BLA.
DBV Technologies (NASDAQ: DBVT - Get Free Report) and XTL Biopharmaceuticals (NASDAQ: XTLB - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation. Profitability This table compares DBV Technologies and
Châtillon, France, September 3, 2026 DBV Technologies to Participate in Upcoming September Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in September: 2026 Cantor Global Healthcare Conference – September 9, 2026 Format: Fireside Chat Time: 1:00pm ETLocation: New York, NY Citi's 2026 Biopharma Back to School Conference – September 10, 2026 Format: 1 on 1 MeetingsLocation: New York, NY H.C. Wainwright 28 th Annual Global Investment Conference – September 15, 2026 Format: Fireside ChatTime: 3:00pm ETLocation: New York, NY Live webcasts of the fireside chats will be available on the Events section of the Company's website here and will be available for 90 days after the event.
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026